The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE
George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’
George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’View Video
Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America
Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin AmericaView Video

Latest Share Chat

AIM WINNERS & LOSERS: Omega Covid test gets CE mark; Creo revenue up

Thu, 03rd Feb 2022 11:00

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday.

----------

AIM - WINNERS

----------

Omega Diagnostics Group PLC, up 24% at 11.76 pence, 12-month range 6.50p-117.98p. The Alva, Scotland-based medical diagnostics company successfully attains a CE mark for its Visitect Covid-19 antigen test. "The company remains in discussions with commercial partners about how best to service the European market and other territories that recognise the CE mark. Omega's commercial offering will be via B2B partners and distributors, and not through a direct-to-consumer strategy," Omega adds.

----------

Creo Medical Group PLC, up 16% at 137.00 pence, 12-month range 116.50p-236.00p. The medical device company, with a focus on surgical endoscopy expects revenue for 2021 to top expectations at "just over" GBP25 million from GBP9.4 million in 2020.

----------

AIM - LOSERS

----------

Actual Experience PLC, down 15% at 12.90p, 12-month range 12.00p-135.00p. The Bath-based analytics-as-a-service company says its annual loss widens to GBP5.9 million in 2021 from GBP5.0 million in 2020. Revenue declines 11% to GBP1.7 million from GBP2.0 million. "Our sales team are engaged, directly or with partners, in multiple sales opportunities. Our clear focus in the coming months is to convert these opportunities to recurring 'continuous improvement' revenue streams," the company explains. Actual Experience accepts that shareholders have been "frustrated" with progress to date. "However, one of these lessons is that sales cycles will typically be longer than initially expected and therefore our planning has been adjusted to accommodate this timing," the company adds. Shares hit their 12-month low on Thursday.

----------

By Eric Cunha; ericcunha@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

Related Shares

More News
24 Apr 2024 16:04

TRADING UPDATES: ActiveOps sales up; Sancus turnover jumps

(Alliance News) - The following is a round-up of trading updates by London-listed companies, issued on Wednesday and not separately reported by Allian...

1 Mar 2024 14:06

Creo device used in 'groundbreaking' lung cancer procedure

(Sharecast News) - Creo Medical Group announced a significant milestone in the field of minimally-invasive surgical endoscopy for cancer patients on F...

1 Mar 2024 13:34

EARNINGS AND TRADING: Dar Global celebrates "outstanding" year

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Friday and not separately reported...

7 Feb 2024 11:49

Creo Medical FY revenues up double digits

(Sharecast News) - Medical device company Creo Medical said on Wednesday that 2023 was "a pivotal year" for the firm, with new products supporting "st...

7 Feb 2024 10:54

Creo Medical makes "considerable strides" toward 2025 break-even goal

(Alliance News) - Creo Medical Group PLC on Wednesday said that cost controls and new product sales had supported strong growth in 2023, as the compan...

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.